Chai Discovery

Chai Discovery builds an AI platform for de novo antibody design and molecule discovery for biologics research.

Chai Discovery builds frontier AI that predicts and reprograms biochemical interactions. Its platform supports de novo antibody design, molecular modeling, and biologics discovery, helping teams design novel therapeutic molecules with less trial-and-error.

BiOptic

BiOptic software lets AI agents screen drug molecules for potency, safety and deal value, automating pharma asset triage and diligence.

BiOptic runs AI agents that process molecular data, clinical results and economics to rank drug assets. The system checks patents, papers and biotech pipelines to speed up scouting and due diligence. It generates drug candidates and supports licensing and commercialization steps.

Manas AI

Manas AI is a technology company using advanced AI and computational chemistry to accelerate drug discovery for cancer and rare diseases.

Manas AI is a drug discovery company that uses artificial intelligence and computational chemistry to accelerate the development of new medicines. The company combines proprietary AI models, advanced molecular docking techniques, and biological expertise to identify promising drug candidates for cancer and rare diseases. Manas AI’s platform generates custom chemical libraries and employs AI filters to rapidly select high-potential therapeutic compounds. Through a partnership with Microsoft, the company leverages cloud computing to perform molecular docking at speeds 100 times faster than traditional methods. Manas AI is currently focused on developing treatments for aggressive cancers, with plans to expand into other disease areas in the future.

Owkin

Owkin is a company that uses AI, machine learning, and medical research to accelerate the development of new treatments and therapies.

Owkin builds AI systems that study real-world patient data to uncover how diseases work and how people respond to therapies. Its software finds new drug targets, predicts treatment outcomes, and supports trial design so researchers can decide faster which medicines to advance. By linking hospitals, labs, and drug developers through intelligent agents, it helps turn complex medical data into diagnostics and therapies that reach patients sooner.

Atomwise

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered using an Artificial intelligence (AI) engine.

Atomwise uses artificial intelligence to search through massive libraries of small molecules and find drug candidates that can bind to disease targets. Its platform helps research teams choose better compounds earlier, cut down failed experiments, and move promising therapies into preclinical development more quickly and efficiently.